This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Oncolytics Pumps Stock With Worsening Lung Cancer Drug Data

Stocks in this article: ONCY

CALGARY ( TheStreet) -- Oncolytics Biotech continues to mislead investors about the clinical profile of its experimental cancer drug Reolysin. The company's latest stock-promoting stunt: Issuing a press release Monday (ONCY) claiming "positive final" results from a mid-stage study of Reolysin in lung cancer. Reality check: The new Reolysin data are actually worse than what Oncolytics reported last March.

Oncolytics says the final analysis of the phase II study involves 25 patients with squamous cell carcinoma of the lung. All the patients were treated with Reolysin in combination with the chemotherapy drugs carboplatin and paclitaxel. The study has no control arm, making results clinically meaningless.

Per today's press release, of the 25 patients evaluated, 10 patients showed partial tumor shrinkage, equal to an overall response rate of 40%.

Last March, Oncolytics reported results from 21 patients in the same study. At that time, nine patients reported partial tumor shrinkage for an overall response rate of 43%.

So, in about five months, Oncolytics managed to enroll another four lung cancer patients into this trial, with just one additional tumor response.

Oncolytics actually first reported results from this lung cancer study in February. At that time, the company had enrolled 20 patients with 9 showing tumor shrinkage, or an overall response rate of 45%.

According to, the Reolysin lung cancer study was designed to enroll 55 patients. The study is no longer recruiting patients, so if today's results are "final" -- as Oncolytic claims -- where are the missing 30 patients?

-- Reported by Adam Feuerstein in Boston.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,356.87 +288.00 1.69%
S&P 500 2,012.89 +40.15 2.04%
NASDAQ 4,644.3120 +96.4780 2.12%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs